本帖最后由 老马 于 2012-1-13 21:20 编辑 4 h3 c' f) T" v, V& h+ a( h
7 {4 L3 O* p: J) v% e
爱必妥和阿瓦斯丁的比较
) L' W0 D8 r- I& h# s* i( x
3 J; f2 j, M$ y2 z* f3 I. xhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/* S" B! e$ q- _5 n- k6 V F$ \
) v) L+ S1 e' D
. D/ Y# W2 A$ j" F
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
4 t, @: `2 z" Q3 a- N" V1 O==================================================$ n3 ^# j0 P( X2 a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)" A: ]1 p/ n0 U# e3 s6 M: l
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.& M3 a# F0 R3 V9 Z. G
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
5 b7 |# Z3 T' [1 k0 x0 `
|
显身卡
